

Monday, November 14, 2005 • Indianapolis, IN.

Name _____

Affiliation _____

Address _____

City _____ State _____ Zip _____

Daytime Phone () _____ Ext. _____

LIMITED AVAILABILITY. RESERVE YOUR COMPLIMENTARY SEAT TODAY.
 e-mail IEINSEMINAR@aol.com OR FAX: 978-632-1573 OR CALL 978-632-7361

Please detach along perforation.

Program Overview

A challenge facing asthma care specialists is how they can optimize the clinical outcomes of patients with asthma. Recent epidemiologic studies have demonstrated that even the best asthma specialists have difficulty managing patients with moderate to severe disease. New assessment tools are available to enhance evaluation of asthma patients. A working knowledge of these assessment tools is essential to optimize asthma outcomes. Despite current asthma therapies, pathologic progression remains a significant issue. New studies have raised concerns about current paradigms for asthma management, the approaches to therapeutic interventions being reassessed based upon new data. This seminar is designed to assist asthma specialists in both assessment of asthma patients and optimization of asthma management reviewing recently published investigations with an emphasis on IgE-mediated disease.

Program Objectives

Upon completion of this program participants will be able to:

- Describe assessment tools and their role in determining optimal asthma outcomes
- Explain the relationships between pathology and clinical causes of asthma progression
- Evaluate the current options for care of asthma patients having mild to severe disease including disease morbidity and therapeutics

Target Audience

This activity is intended for physicians who specialize in asthma care, including pulmonologists and allergists, in addition to those physicians whose practice encompasses large numbers of asthma patients and who desire to learn more about new therapeutic approaches available from asthma specialists.

ACAAI American College of
Allergy, Asthma & Immunology



Immunology Educational Institute of New England

CME Dinner Meeting November 14

PRE-REGISTER NOW (SEE REVERSE SIDE FOR DETAILS)

SUPPORTED BY AN UNRESTRICTED GRANT FROM
GENENTECH, INC. and NOVARTIS PHARMACEUTICALS CORPORATION

EVOLVING APPROACHES TO OPTIMIZE ASTHMA OUTCOMES

PRESORTED
FIRST CLASS MAIL
U.S. POSTAGE
PAID
Clifton, NJ
Permit No. 1104

FIRST CLASS MAIL

Monday, November 14, 2005
Ruth's Chris Steak House

9445 Threel Road
Indianapolis, IN 46240
317-844-1155

Agenda:

6:00-6:25PM:
Registration, dinner served

6:25-6:30PM:
Introduction
Lawrence M. DuBuske, MD, Moderator

6:30-7:30PM:
Asthma outcomes: epidemiology and assessment -
where are we today?
Pinkus Goldberg, MD

7:30-8:30PM:
Therapeutic controversies in asthma:
1. Mild persistent disease - new considerations
2. High-dose versus low-dose inhaled corticosteroids
- What are the risks versus benefits?
3. Severe persistent disease - current options for care
Lawrence M. DuBuske, MD

8:30-9:30PM:
Asthma progression: pathology versus clinical cause -
therapeutic implications
Gailen D. Marshall, MD, PhD, FACP

9:30-10:30PM:
Panel discussion and Question & Answer
Practical application of outcomes assessment
Faculty and moderators

FACULTY

Lawrence M. DuBuske, MD
Clinical Instructor in Medicine, Harvard Medical School; Consultant in Allergy, Brigham and Women's Hospital, Boston, MA; Director, Immunology Research Institute of New England Gardner, MA.

Pinkus Goldberg, MD
Clinical Assistant Professor of Medicine, Indiana University Medical Center Allergy, Asthma, and Clinical Immunology Associates, Indianapolis, IN

Gailen D. Marshall, MD, PhD, FACP
Professor of Medicine and Pediatrics, Director, Division of Clinical Immunology and Allergy, University of Mississippi Medical Center Jackson, MS

ACCREDITATION

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the American College of Allergy, Asthma & Immunology (ACAAI) and the Immunology Educational Institute of New England. The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians. The ACAAI takes responsibility for the content, quality, and scientific integrity of this CME activity. The ACAAI designates this educational activity for a maximum of 4 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actively spent in the educational activity.

ACAAI

AFFIX
1ST CLASS
POSTAGE
HERE



Program Coordinator

Immunology Educational Institute of New England
358 Elm Street
Gardner, MA 01440